RxDoctor Payments Data

Dolores Lebron-Gallagher, PA

Physician Assistant · Las Vegas, NVNPI 1831134527

Payments from drug & device makers

$2,091in general payments, 2019–2025

Across 24 payments — averaging $87.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$363
  • Boehringer Ingelheim$335
  • Novo Nordisk$208
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$194
  • Johnson & Johnson$176
  • Abbott$164
  • plus $650 from 7 others

What the payments were for

  • Food & beverage$2,091100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,091 in reported general payments places this provider in the 75th percentile of 881 physician assistant providers in Nevada.

See all physician assistant providers in Nevada

Medicare billing

Part B allowed, 2024
$10,458
Medicare patients
84
Services billed
138

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban606$687,767
XareltoRivaroxaban116$123,829
JardianceEmpagliflozin49$79,358
EntrestoSacubitril/Valsartan63$75,667
Praluent PenAlirocumab32$23,545
Repatha SyringeEvolocumab16$10,223
Metoprolol Succinate758$7,252
Torsemide245$5,373
Atorvastatin Calcium564$5,116
Ranolazine ErRanolazine43$4,086
Rosuvastatin Calcium385$4,045
Carvedilol397$4,012
Furosemide317$2,532
Losartan Potassium218$1,953
Potassium Chloride205$1,864

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$176$123,829116 claims
Boehringer IngelheimJardiance$335$79,35849 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 881 physician assistant providers in Nevada.

Other physician assistant in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →